Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6,681 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy, Safety, and Immunogenicity of the MATISSE (Maternal Immunization Study for Safety and Efficacy) Maternal Respiratory Syncytial Virus Prefusion F Protein Vaccine Trial.
Simões EAF, Pahud BA, Madhi SA, Kampmann B, Shittu E, Radley D, Llapur C, Baker J, Pérez Marc G, Barnabas SL, Fausett M, Adam T, Perreras N, Van Houten MA, Kantele A, Huang LM, Bont LJ, Otsuki T, Vargas SL, Gullam J, Tapiero B, Stein RT, Polack FP, Zar HJ, Staerke NB, Padilla MD, Richmond PC, Sarwar UN, Baber J, Koury K, Lino MM, Kalinina EV, Li W, Cooper D, Anderson AS, Swanson KA, Gurtman A, Munjal I; MATISSE (Maternal Immunization Study for Safety and Efficacy) Clinical Trial Group. Simões EAF, et al. Among authors: cooper d. Obstet Gynecol. 2025 Feb 1;145(2):157-167. doi: 10.1097/AOG.0000000000005816. Epub 2025 Jan 2. Obstet Gynecol. 2025. PMID: 39746212 Free PMC article. Clinical Trial.
Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F Vaccine When Coadministered With a Tetanus, Diphtheria, and Acellular Pertussis Vaccine.
Peterson JT, Zareba AM, Fitz-Patrick D, Essink BJ, Scott DA, Swanson KA, Chelani D, Radley D, Cooper D, Jansen KU, Dormitzer PR, Gruber WC, Gurtman A. Peterson JT, et al. Among authors: cooper d. J Infect Dis. 2022 Jun 15;225(12):2077-2086. doi: 10.1093/infdis/jiab505. J Infect Dis. 2022. PMID: 34637519 Free PMC article. Clinical Trial.
Phase 1/2 Randomized Study of the Immunogenicity, Safety, and Tolerability of a Respiratory Syncytial Virus Prefusion F Vaccine in Adults With Concomitant Inactivated Influenza Vaccine.
Falsey AR, Walsh EE, Scott DA, Gurtman A, Zareba A, Jansen KU, Gruber WC, Dormitzer PR, Swanson KA, Jiang Q, Gomme E, Cooper D, Schmoele-Thoma B. Falsey AR, et al. Among authors: cooper d. J Infect Dis. 2022 Jun 15;225(12):2056-2066. doi: 10.1093/infdis/jiab611. J Infect Dis. 2022. PMID: 34931667 Free PMC article. Clinical Trial.
A Randomized Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine.
Walsh EE, Falsey AR, Scott DA, Gurtman A, Zareba AM, Jansen KU, Gruber WC, Dormitzer PR, Swanson KA, Radley D, Gomme E, Cooper D, Schmoele-Thoma B. Walsh EE, et al. Among authors: cooper d. J Infect Dis. 2022 Apr 19;225(8):1357-1366. doi: 10.1093/infdis/jiab612. J Infect Dis. 2022. PMID: 34932102 Free PMC article. Clinical Trial.
A Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine With and Without Adjuvant in Healthy Older Adults.
Baber J, Arya M, Moodley Y, Jaques A, Jiang Q, Swanson KA, Cooper D, Maddur MS, Loschko J, Gurtman A, Jansen KU, Gruber WC, Dormitzer PR, Schmoele-Thoma B. Baber J, et al. Among authors: cooper d. J Infect Dis. 2022 Dec 13;226(12):2054-2063. doi: 10.1093/infdis/jiac189. J Infect Dis. 2022. PMID: 35543281 Free PMC article. Clinical Trial.
Safety and immunogenicity of a booster dose of a 3-antigen Staphylococcus aureus vaccine (SA3Ag) in healthy adults: A randomized phase 1 study.
Marshall H, Nissen M, Richmond P, Shakib S, Jiang Q, Cooper D, Rill D, Baber J, Eiden J, Gruber WC, Jansen KU, Anderson AS, Zito ET, Girgenti D. Marshall H, et al. Among authors: cooper d. J Infect. 2016 Nov;73(5):437-454. doi: 10.1016/j.jinf.2016.08.004. Epub 2016 Aug 9. J Infect. 2016. PMID: 27519620 Clinical Trial.
Bivalent RSVpreF Vaccine in Adults 18 to <60 Years Old With High-Risk Conditions.
Davis M, Towner W, DeHaan E, Jiang Q, Li W, Rahman F, Patton M, Wyper H, Lino MM, Sarwar UN, Majid-Mahomed Z, Mehta S, Howitt W, Cannon K, Kalinina E, Cooper D, Swanson KA, Anderson AS, Gurtman A, Munjal I. Davis M, et al. Among authors: cooper d. Clin Infect Dis. 2024 Nov 11:ciae550. doi: 10.1093/cid/ciae550. Online ahead of print. Clin Infect Dis. 2024. PMID: 39523547
6,681 results